Biotechnology News and Research

RSS

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

2 Jul 2013

Low levels of amyloid fibres are more harmful to health, say scientists

Neurodegenerative diseases such as Alzheimer's could be better understood thanks to insight into proteins linked to such conditions, a study suggests.

2 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Mary Ann Liebert announces launch of 3D Printing and Additive Manufacturing journal

Mary Ann Liebert, Inc., publishers announces the launch of 3D Printing and Additive Manufacturing, a highly innovative, peer-reviewed journal on this rapidly growing disruptive technology.

29 Jun 2013

TSRI professor receives $3.75M "mega-grants" from Russian government

Valery Fokin, professor in the Department of Chemistry at The Scripps Research Institute (TSRI), has been awarded a prestigious grant from the Russian government for $3.75 million over three years, with the possibility of a two-year renewal.

28 Jun 2013

Study shows "bioadhesive" coating can increase intestinal uptake of protein-based drugs

For protein-based drugs such as insulin to be taken orally rather than injected, bioengineers need to find a way to shuttle them safely through the stomach to the small intestine where they can be absorbed and distributed by the bloodstream.

28 Jun 2013

RUCDR Infinite Biologics receives $44.5 million Cooperative Agreement award from NIMH centre

RUCDR Infinite Biologics, the world's largest university-based biorepository, received a $44.5 million Cooperative Agreement award from the National Institute of Mental Health earlier this month to support its NIMH Center for Collaborative Genomics Research on Mental Disorders, which provides services to NIMH-funded scientists engaged in genomic research on mental disorders.

28 Jun 2013

Study reports new mechanism that regulates specification of lymphocytes

Scientists at an Academy of Finland Centre of Excellence have discovered a new mechanism regulating the immune response that can leave a person susceptible to autoimmune diseases.

28 Jun 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Scientists make important step forward to find cure for cancer

Scientists at the University of East Anglia have made a major advancement in understanding tissue development that has important implications for cancer.

27 Jun 2013

FDA grants fast track designation to Genervon Biopharmaceuticals for ALS drug GM604

In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.

27 Jun 2013

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys AG and Celgene Corporation today announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

27 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.

25 Jun 2013

Study suggests new ways to maximize delivery of RNA strands

Nanoparticles that deliver short strands of RNA offer a way to treat cancer and other diseases by shutting off malfunctioning genes. Although this approach has shown some promise, scientists are still not sure exactly what happens to the nanoparticles once they get inside their target cells.

25 Jun 2013

Researchers find RNA molecule that interferes with lipoprotein production, reduces hyperlipidemia

Hyperlipidemia, a condition with high levels of fats circulating in the bloodstream, is a known risk factor for various cardiovascular and metabolic disorders. While the Western diet often contributes to high levels of lipids such as cholesterol and triglycerides, over-production of the body's own lipoproteins can lead to hyperlipidemia, independent of food intake.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

Driven by increasing demand for its cloud-based data insights solution, Comprehend Systems further expands its reach in the clinical research space with a partnership with Merge Healthcare's eClinical Solutions division.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Biotechnology News and Research

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Low levels of amyloid fibres are more harmful to health, say scientists

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Mary Ann Liebert announces launch of 3D Printing and Additive Manufacturing journal

TSRI professor receives $3.75M "mega-grants" from Russian government

Study shows "bioadhesive" coating can increase intestinal uptake of protein-based drugs

RUCDR Infinite Biologics receives $44.5 million Cooperative Agreement award from NIMH centre

Study reports new mechanism that regulates specification of lymphocytes

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Scientists make important step forward to find cure for cancer

FDA grants fast track designation to Genervon Biopharmaceuticals for ALS drug GM604

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

Study suggests new ways to maximize delivery of RNA strands

Researchers find RNA molecule that interferes with lipoprotein production, reduces hyperlipidemia

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News